Recommendations for bone marker standards in osteoporosis: What, why and where to now?

Annals of Clinical Biochemistry

Volumn 48, Issue 2, 2011, Pages 91-92

  Vasikaran, Samuel D ^a,b   Cooper, Cyrus ^c,d   Kanis, John A ^e  

^a PATHWEST LABORATORY MEDICINE   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PARATHYROID HORMONE[1-34];

AGING; BONE DENSITY; EDITORIAL; HUMAN; OSTEOLYSIS; OSTEOPOROSIS; PREVALENCE; PRIORITY JOURNAL;

BIOLOGICAL MARKERS; BONE AND BONES; HUMANS; OSTEOPOROSIS; REFERENCE STANDARDS;

EID: 79952997227     PISSN: 00045632     EISSN: 00045632     Source Type: Journal    
DOI: 10.1258/acb.2011.010286     Document Type: Editorial

References (15)

1. Burge R, Dawson-Hughes B, Solomon D, Wong J, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 2007;22:465-75
2. Consensus Development Conference: diagnosis, prophylaxis and treatment of osteoporosis. Am J Med 1993;94:646-50
3. Kanis JA, Melton LJ, Christiansen C, Johnston C, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res 1994;9:1137-41 (Pubitemid 24985932)
4. Kanis JA, McCloskey EV, Johansson H, Oden A, Melton LJ, Khaltaev N. A reference standard for the description of osteoporosis. Bone 2008;42:467-75
5. Compston J, Cooper A, Cooper C, et al. for the National Osteoporosis Guideline Group. Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas 2009;62:105-8
6. Vasikaran SD, McCloskey EV, Kahn S, Kanis JA. Intra-individual variation in fasting urinary calcium- and hydroxyproline-creatinine ratios measured in metabolic bone clinic patients as both outpatients and inpatients. Ann Clin Biochem 1994;31(3):272-6 (Pubitemid 24167832)
7. Hannon R, Eastell R. Preanalytical variability of biochemical markers of bone turnover. Osteoporos Int 2000;11:S30-44
8. Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 2003;18:1051-6 (Pubitemid 37294942)
9. Reginster J-Y, Sarkar S, Zegels B, et al. Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk. Bone 2004;34:344-51 (Pubitemid 38177616)
10. Sarkar S, Reginster J-Y, Crans GG, Diez-Perez A, Pinette KV, Delmas PD. Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk. J Bone Miner Res 2004;19:394-401 (Pubitemid 38787394)
11. Bauer DC, Black DM, Garnero P, et al. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res 2004; 19:1250-8 (Pubitemid 41094365)
12. Delmas PD, Munoz F, Black DM, et al. The HORIZON-PFT Research Group. Effects of yearly zoledronic acid 5 mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis. J Bone Miner Res 2009;24:1544-51
13. Arlot M, Meunier PJ, Boivin G, et al. Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. J Bone Miner Res 2005;20:1244-53 (Pubitemid 40863814)
14. Vasikaran S, Eastell R, Bruyère O, et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int 2011;22:391-420
15. Seibel MJ, Lang M, Geilenkeuser WJ. Interlaboratory variation of biochemical markers of bone turnover. Clin Chem 2001;47:1443-50 (Pubitemid 32678824)